Newcells Biotech joins StemBANCC consortium - Newcells

Retinal platform

An in vitro, light responsive, retinal model for accurate predictions of in vivo outcomes you can have confidence in.

aProximateTM

Kidney platform

The most advanced near-physiological high throughput kidney proximal tubule cells (PTC) model to investigate drug transport modalities in vitro.

Lung epithelia model

Lung model

A model to investigate airway physiology, viral infection, drug safety and environmental impacts on lung airway epithelia.

Sinusoid iPSC-derived Liver model

Liver model

We are developing a model of liver sinusoid derived from human induced pluripotent stem cells (iPSC).

Published 01st September 2017 | News

Newcells Biotech joins StemBANCC consortium

Newcells Biotech has joined the StemBANCC project, a pan-EU consortium made up of major pharmaceutical and academe groups. StemBANCC’s goal is to generate 1,500 iPSC lines from 500 people, characterise them in terms of their genetic, protein, and metabolic profiles, and make them available to researchers for toxicology testing and disease modelling.

The raw materials for the project are largely skin and blood samples taken from patients with certain diseases, people who display adverse reactions to drugs, and healthy individuals. There is a strong focus on peripheral nervous system disorders (especially pain); central nervous system disorders (e.g. dementias); neuro-dysfunctional diseases (e.g. migraine, autism, schizophrenia, and bipolar disorder); and diabetes. The project also investigates the use of human iPSCs for toxicology testing; using iPSCs to generate liver, heart, nerve and kidney cells.

Share This:
Tweet Post Share